II. Indications
- Diabetes Insipidus
- Control of Hemophilia A related bleeding
- Primary Nocturnal Enuresis
- Nocturia (non-medication options are preferred)
-
Von Willebrand's Disease
- Type I (and in Type 2N) cases prior to surgery and in cases of Trauma
- Other VWD forms (Type 2, Type 3 and pseudo-VWF) will not respond to DDAVP
- May have paradoxical lowering of VWF
III. Contraindications
- Impaired Renal Function
- Congestive Heart Failure
IV. Mechanism
- Synthetic ADH replacement Hormone (analogue of Vasopressin)
- Potent antidiuretic
- No Vasopressor activity
- Urine Volume decreases by resorbing water at distal renal tubules
- Increases release of Von Willebrand FactorProtein (stored in Weibel-Palade bodies)
V. Pharmacokinetics
- Duration of action: 12 hours
VI. Dosing: Nocturnal Enuresis
-
General
- If effective, may continue for 3-6 months
- Maintain dose for 4-6 weeks and then slowly taper off over 6 months
- Discontinue slowly (e.g. 10 mcg/month)
- Reduces risk of relapse
- Consider in combination with Bed-Wetting Alarm or Oxybutynin
- Desmopressin Intranasal (standard, high dose)
- Not recommended due to risk of Hyponatremia (from Water Intoxication)
- Initial: 5 mcg spray each nostril qhs
- Increase as needed up to 20 mcg each nostril qhs
- Desmopressin Intranasal (Noctiva, low dose)
- Each spray delivers 0.83 to 1.66 mcg
- Marketed for Nocturia in adults (but other non-medication approaches are preferred)
- Expensive: $425/month in 2018
- Desmopressin Oral
- Initial: 0.2 mg PO qhs
- Use lowest effective dose
- Increase as needed to 0.6 mg at bedtime
VII. Dosing: Diabetes Insipidus
- Nasal Spray: 10-40 mcg daily (or divided 2-3 times per day)
- Intranasal 5 mcg equivalent to 0.1 mg oral
- Oral Tablet: 0.05 to 1.2 mg orally daily (or divided 2-3 times daily)
- Subcutaneous or IV: 2-4 mcg/day IV/SC divided twice daily
VIII. Dosing: Von Willebrand Disease or Hemophilia A
- IV: 0.3 mcg/kg IV over 15 to 30 minutes
- Intranasal concentrated dDAVP (Stimate)
- Weight <50kg: 150 mcg intranasally (1 spray in SINGLE nostril)
- Weight >50kg: 300 mcg intranasally (1 spray EACH nostril)
-
Pharmacokinetics specific to VWF release
- Onset of action within 30-60 minutes with duration of 6-12 hours
- Do not repeat more often than every 24 to 48 hours due to Hyponatremia risk (as well as tachyphylaxis)
IX. Adverse Effects
- Nasal irritation or Epistaxis with nasal spray
- Behavior changes
- Aggressive behavior
- Nightmares
-
Nocturia
- Administer at night to reduce Nocturia
- Severe Hyponatremia (Water Intoxication)
- Seizures (with high dose Desmopressin nasal sprays)
X. Labs
-
Serum Sodium
- Obtain baseline, at 7 days, 30 days and periodically (esp. after dose changes)
XI. Efficacy: Nocturnal Enuresis
- Most effective in over age 8-9 years (60-70% respond)
- Also more effective if only a few wet nights and normal Bladder capacity
- High relapse rate (>80%); Reduced if slowly tapered - see doing above
XII. Disadvantages
- Expensive
- Severe Hyponatremia risk
XIII. Drug Interactions: Increased risk of Hyponatremia
- Diuretics
- Corticosteroids (inhaled or systemic)
- Selective Serotonin Reuptake Inhibitors (SSRI)
- Chronic NSAIDs
XIV. References
- Deloughery and Orman in Majoewsky (2013) EM:Rap 13(9): 1-4
- Tullus (1999) Acta Paediatr 88:1274-8 [PubMed]
- Kruse (2001) BJU Int 88:572-6 [PubMed]
- Robson (2007) J Urol 178: 24-30 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
desmopressin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
DESMOPRESSIN 10 MCG/0.1 ML SPR | Generic | $7.86 per ml |
DESMOPRESSIN ACETATE 0.1 MG TB | Generic | $0.33 each |
DESMOPRESSIN ACETATE 0.2 MG TB | Generic | $0.42 each |